TP53 positive MRD status in patients with AML, for example, has been associated with a significantly worse survival (median overall survival, 6.4 months vs 21.7 months, p = 0.042) both in patients with TP53-mutated AML and myelodysplastic syndrome receiving HMA as frontline therapy (n = 24) prior allo-SCT (Olivier et al., 2010; Malagola et al., 2023; Song et al., 2023; Chattopadhyay et al., 2024; Park et al., 2024; Sahasrabudhe and Mims, 2024). The gene discussed is TP53; the disease is myelodysplastic syndrome.